Skip to main content
. 2015 Nov 25;10(11):e0142212. doi: 10.1371/journal.pone.0142212

Fig 4. PM-242H inhibits development of allergic lung disease in Balb/c mice.

Fig 4

Mice were treated every other day for two weeks with vehicle (DLPC) or one of two doses of PM-242H (242H; 5 mg or 50 μg i.n.) and challenged with A. niger conidia (AN) or PBS i.n. after which the allergic airway disease phenotype was assessed as in Fig 3. (a) Airway responsiveness (*: P < 0.05 determined by ANOVA), (b) bronchoalveolar lavage fluid inflammatory cells, (c) total lung IL-4-secreting cells, and (d) fungal colony forming units (CFU) recovered from the lungs of infected mice are shown. *: P < 0.05 determined by Kruskal-Wallis test (n = 4 mice/treatment group). Data are from one of 4 independent and comparable biological experiments.